Skip to main content
. 2020 Oct 13;12(19):19546–19562. doi: 10.18632/aging.103904

Figure 3.

Figure 3

Evaluation of the effect of iPSCs/MSCs-Exos on HCECs. (A) HCECs were treated with 500 μg/ml iPSCs/MSCs-Exos or DMEM/F12 for 24 h and followed with apoptosis assay. (B) The percentage of cells at each stage is shown by the bar graphs. The iPSCs-Exos treatment group exhibited a lower proportion of apoptotic cells and a higher proportion of living cells than the control and MSCs-Exos treatment group. (C) HCECs were treated with 500 μg/ml iPSCs/MSCs-Exos for 12 h and followed with a scratch experiment. ImageJ was used to measure the cell migration area. (D) The cell migration rate was quantified at 6 and 12 h and is shown by bar graphs. The migration area was highest in iPSCs-Exos treated group at both 6 h and 12 h. (E) HCECs were treated with 500 μg/ml iPSCs/MSCs-Exos or DMEM/F12 for 72 h. Cell viability was detected by a CCK-8 kit and the results are shown with line graphs. iPSCs/MSCs-Exos increased cell viability at 24 h, 48 h and 72 h compared with that of the control. The data shown here are the mean ± SEM from three independent experiments. * P<0.05, ** P<0.01, *** P<0.001.